Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Approves First Intermediate-Risk Indication For TAVR

Executive Summary

The expanded indication for Edwards' Sapien XT and Sapien 3 arrives about when the company had predicted.

Advertisement

Related Content

Relentless Rise Of Transcatheter Tech: Heart Valve Repair Turns Back On Open Surgery
US FDA Green-Lights Medtronic's CoreValve Evolut For Intermediate Risk
ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve
Earnings Winners and Losers: BSX, EW, ABT, JNJ, SYK, ZBH
Edwards, Boston Sci Make TAVR Progress In Europe
OUS Approvals Analysis: Expanded CoreValve Indication And Zika IVDs Among August’s CE Marks
ACC 2016 BEST OF THE REST: Surgery Trials, More CoreValve Data, Leadless Pacemakers, Drug-Filled Stents, And More
Expanded Indication For Edwards’ Sapien 3 Squarely In Sight
TAVR Researchers Look To Lower-Risk Patients, Less Data Demands

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT103732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel